Mosapride, a selective serotonin 5-HT4 receptor agonist, and alogliptin, a selective dipeptidyl peptidase-4 inhibitor, exert synergic effects on plasma active GLP-1 levels and glucose tolerance in mice
详细信息 查看全文
- 作者：Katsunori Nonogaki ; katsu@trc.med.tohoku.ac.jp" class="auth_mail" title="E-mail the corresponding author ; Takao Kaji
- 关键词：Mosapride ; 5-HT4 receptor agonist ; Alogliptin ; DPP-4 inhibitor ; GLP-1 ; Glucose tolerance
- 刊名：Diabetes Research and Clinical Practice
- 出版年：2015
- 出版时间：December 2015
- 年：2015
- 卷：110
- 期：3
- 页码：e18-e21
- 全文大小：374 K
文摘
- •
Mosapride citrate slightly increased plasma GLP-1 levels independent of feeding.
- •
Mosapride citrate plus alogliptin enhanced the increases in active GLP-1 levels.
- •
Mosapride citrate plus alogliptin improved glucose tolerance.
- •
The 5-HT4 receptor agonist and DPP-4 inhibitor exert synergic effects.